TM6SF2 and Cirrhosis: A previous study performed on the general population confirmed that an increased PRS based on PNPLA3 rs738409, TM6SF2 rs58542926, and HSD17B13 rs72613567 conferred a higher risk of both cirrhosis and HCC development, with a higher risk of HCC compared to the risk of cirrhosis (29-fold higher for HCC vs. 12-fold higher for cirrhosis) [18].